Murali Prahalad, Ph.D.
President and Chief Executive Officer
The President and CEO of Epic Sciences, Murali Prahalad, Ph.D., has more than 14 years of experience in the tech and life science industries.
Prior to joining Epic, Dr. Prahalad served as Vice President of Corporate Strategy at Life Technologies, where he helped shape the organic and inorganic investment priorities across the company’s research tools, clinical diagnostic and applied market portfolios. His experience at Life Technologies ranged from mergers and acquisitions to in-licensing and general management, where he led large businesses spanning genomics and cell biology. As a general manager, he grew revenue and profit by building stronger teams, driving innovation and managing operations for both consumable and instrument portfolios. These included Molecular Probes®, transfection (Lipofectamine®), custom primers and research antibodies, Life Technologies imaging instrumentation (FLoID®, TALI®, Countess®) and flow cytometry platforms (Attune®). Before Life Technologies, Dr. Prahalad was Vice President of Business Development at Sequenom, Inc.
Dr. Prahalad is proficient in several languages, including Japanese, French and Kannada. He received a Ph.D. in biochemistry and molecular pharmacology as well as an M.S. in medical sciences from Harvard University. He also possesses a B.S. (Hons) in cellular & molecular biology and economics from the University of Michigan.
Chief Commercial Officer
Katherine Atkinson is the Chief Commercial Officer at Epic Sciences. Ms. Atkinson has over two decades of life science and healthcare experience in a variety of sales leadership roles. Prior to joining Epic, Ms. Atkinson was the vice president of business development at Edico Genome, where she established a global channel network and managed strategic partnerships. Prior to Edico Genome, she worked for Illumina. During her tenure at Illumina, she oversaw numerous teams, including molecular biology/PCR sales, Inside Sales, Latin America, and most recently Global Channel Partners, where she developed a high performing Channel Partner program from the ground up, encompassing more than 70 partners covering 130 countries worldwide. Ms. Atkinson has also held positions at Fisher Scientific, Thermo Fisher, and Beckman Coulter.
Ms. Atkinson holds a B.A. in Broadcast Journalism and Public Speaking from the University of Houston.
Pascal Bamford, Ph.D.
Chief Scientific Officer
Head of Laboratory Operations
Dr. Bamford, Epic’s Chief Scientific Officer and Head of Laboratory Operations, spent his early career developing automated cytology imaging systems at CSSIP in Australia in collaboration with Accumed International of Chicago. He subsequently took on the role of Director of Imaging at MonoGen, where he developed an all-digital, microscopy-based, cervical cancer screening product, which was recognized as the first “killer app” for the field of digital pathology. During his five years at Ventana-Roche, Dr. Bamford held various roles of increasing responsibility in research, digital pathology and assay development, working on fluorescence multiplexing imaging systems and driving several bright field IHC algorithm CE-IVD and 510(k) clearances. More recently, Dr. Bamford led the detection reagent development of Ventana’s next generation staining platform.
Dr. Bamford obtained his Ph.D. from the University of Queensland in St. Lucia, Australia. His research focused on how the cancer-associated changes in DNA structures detected in digital images could be used to automate the process of distinguishing cervical cancer from normal cells. Dr. Bamford is the author of six patents and more than 18 scientific publications.
Chief of Medical Innovation
Head of Translational Research Partnerships
Ryan Dittamore is the Chief of Medical Innovation and Head of Translational Research Partnerships at Epic Sciences. He is a recognized molecular diagnostics leader with extensive scientific, medical and business experience in ideating, developing and commercializing cancer tests.
At Epic Sciences, Mr. Dittamore leads product pipeline development initiatives with a focus on developing novel predictive and monitoring tests targeting critical unmet clinical decisions in metastatic patients. This includes efforts which led to the pioneering development of the Oncotype DX AR-V7 Nucleus Detect test, the first clinically validated predictive test in prostate cancer. Additionally, he is the head of the translational research partnerships team which initiates and executes numerous oncology clinical trials with over 45 academic and government investigators as well as strategic partnerships across more than 250 clinical trials with 65 biopharmaceutical companies.
Mr. Dittamore’s background includes a diverse set of roles spanning over 20 years in the diagnostic and life science industries. He has been involved in research, product development, marketing, business development, sales and global channel management. In addition to his work at Epic Sciences, Mr. Dittamore is a co-chair at BloodPac, part of the Biden Cancer Moonshot initiative. Before his tenure at Epic Sciences, Mr. Dittamore served as Director of Medical Innovation and Disease Lead for Genitourinary (GU) Cancers at Ventana Medical Systems (Roche Tissue Diagnostics). Collectively, his efforts into translational research and product development, have led to over 100 novel abstracts, publications, and patents towards improving patient outcomes.
Mr. Dittamore holds a B.S. in biology from the University of Oregon and an MBA from the University of Massachusetts, Amherst.